ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.15 +12.28%

+$0.21 today

Market cap
$162.29M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 1.16M

Average 0.62M

Returns on capital

ProQR Therapeutics N.V. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-82.1%

avg -62.9%

ROIC

-49.8%

avg -43.3%

ROA

-36.0%

avg -37.7%

Analysis

ROA is currently the strongest return metric at -36.0% versus its period average of -37.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Daniel Anton de Boer

Founder, CEO & Executive DirectorEUR 1.05M43500.00K0.47%

Gerard Platenburg

Co-Founder, Chief Scientific Officer & Executive DirectorEUR 644.84K62——

Golnar Karimian

Head of Hepatology————

Christopher Hart

Chief Data & AI Officer————

Dennis Hom

Chief Financial Officer—51250.00K0.24%

Sandra van der Kolk

Junior Financial Controller————

Sarah Cue Kiely

Vice President of Investor Relations & Corporate Communications————

Sheila Sponselee

Chief People & Operations Officer—42——

Cristina Lopez Lopez

Chief Medical Officer—50——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 31, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

5

$1.34M

Sells

0

$0.00

Net Transaction Value

+$1.34M

Net buying

Most Active

de Boer Daniel Anton

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 31, 26

de Boer Daniel Anton

Direct

Buy$354K
Jul 17, 26

Filius Bart

Direct

Buy$257.9K
Jul 9, 26

de Boer Daniel Anton

Direct

Buy$261K
Jul 7, 26

de Boer Daniel Anton

Direct

Buy$238.5K
Jun 26, 26

Filius Bart

Direct

Buy$231K

Summary

Insiders reported 5 buys worth $1.34M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.34M. de Boer Daniel Anton was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+62.0%
+48.5% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +62.0% over three years. Forward estimates point to Revenue at +48.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does ProQR Therapeutics N.V. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PRQR's management, answered from reported figures.

Who manages PRQR?

ProQR Therapeutics N.V. (PRQR) lists 9 active executives. The top listed executive is Golnar Karimian, Head of Hepatology.

Are PRQR insiders buying or selling?

Recent insider activity shows net buying of $1.36M.